GET DAILY SIGNALSRXD vs XXX: Weighing a Leveraged Inverse Health Care ETF Against a Hybrid Equity and XRP Strategy
Key Takeaways
- RXD is a leveraged inverse ETF seeking -2x the daily return of a U.S. health care index, while XXX blends roughly 75% S&P 500 equities with 25% XRP exposure.
- The two funds do not compete directly; they serve opposite purposes — tactical bearish positioning on health care versus diversified, long-oriented growth exposure.
- RXD carries a 0.95% net expense ratio (6.64% gross) and is subject to daily reset "decay" risk, while XXX charges roughly 0.85%–0.95% with a broader, more diversified profile.
- Sector exposure differs sharply: RXD is concentrated in short pharmaceutical and health care positions, whereas XXX is technology-heavy with meaningful digital-asset exposure.
- Tickeron AI Verdict: XXX — the diversified long-oriented fund is favored over the leveraged inverse product based on structural strength, cost efficiency, and trend consistency.
Introduction
Investors evaluating a defensive stance in health care against broader equity growth that includes digital assets have good reason to review RXD and XXX together. These funds follow fundamentally different strategies: RXD provides daily -2x inverse exposure to U.S. health care, while XXX offers a passive mix of large-cap U.S. stocks and XRP. They suit distinct risk profiles and time horizons, which makes the comparison instructive for seeing how inverse leverage, sector focus, and emerging digital-asset allocations influence positioning in today’s market.
ProShares UltraShort Health Care (RXD) Overview
RXD targets daily results equal to -2x the daily performance of the S&P Health Care Select Sector Index. It is a non-diversified, leveraged inverse product built for short-term tactical use rather than long-term holding. The index includes about 59 health care companies, so the fund’s largest short exposures include names such as LLY, JNJ, ABBV, MRK, UNH, and AMGN. The fund carries a 0.95% net expense ratio (6.64% gross, subject to waiver) and resets leverage daily, which introduces compounding effects over longer periods. Liquidity remains modest, and the structure fits experienced traders with a clear short-term view on health care weakness.
Cyber Hornet S&P 500 and XRP 75/25 Strategy ETF (XXX) Overview
XXX seeks to track, before fees, the S&P 500 and S&P XRP 75/25 Blend Index. It allocates roughly 75% to S&P 500 large-cap equities and 25% to XRP held directly or via a Cayman subsidiary, XRP futures, and exchange-traded products, with direct holdings in cold storage. Rebalancing occurs monthly, though the adviser may adjust more frequently in volatile periods. With around 460 holdings, top equity positions include NVDA, AAPL, MSFT, AMZN, GOOGL, and AVGO. The sector mix is led by technology at nearly 39%, followed by financial services and communication services. The fund charges about 0.85%–0.95% and remains relatively small after its early 2026 launch.
Industry and Thematic Backdrop
Health care and digital assets currently sit at opposite ends of the risk spectrum. Pharmaceutical and managed-care companies continue to face policy, pricing, and regulatory pressure, which can support short-term bearish views yet also leaves room for sharp relief rallies. At the same time, the broader equity market has been driven by technology and artificial-intelligence spending, while XRP and other digital assets have seen renewed interest tied to institutional adoption and regulatory developments. These differing drivers mean the funds respond to separate catalysts—drug-pricing news for one and tech earnings plus crypto sentiment for the other.
Performance and Positioning Comparison
Over recent cycles, RXD returns have moved inversely with health care momentum. Advances in the sector compound losses for the leveraged inverse structure, while pullbacks can produce sharp short-term gains; daily resets, however, can erode value even in sideways markets. XXX, by contrast, has followed the prevailing trend in large-cap growth equities together with XRP volatility, resulting in a broader net-long profile. Relative positioning favors XXX in risk-on environments driven by technology and digital-asset momentum, whereas RXD outperforms only when health care specifically declines—a narrower condition.
Tickeron AI Verdict
Based on observable structural factors, Tickeron’s AI analysis points to XXX over RXD. XXX provides diversified long exposure across hundreds of large-cap equities plus a defined digital-asset allocation, with a moderate fee and no daily leverage reset. RXD remains useful as a tactical hedge but carries the drawbacks of a non-diversified, leveraged inverse vehicle whose daily compounding and 6.64% gross cost structure make it less suitable for most multi-week periods. Overall, XXX’s broader diversification, lower structural drag, and trend consistency give it the edge.
Exploring ETF Comparisons with Tickeron AI Screener
When I compared these two ETFs, I turned to Tickeron’s AI Screener to review their technical profiles and relative performance metrics. The tool helped surface key differences in volatility and trend signals that reinforced the structural analysis. It offers a practical way to scan and filter ETF data efficiently during research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
RXD sees MACD Histogram just turned negative
RXD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 09, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 51 instances where the indicator turned negative. In 46 of the 51 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RXD as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
RXD moved below its 50-day moving average on October 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RXD crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for RXD entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RXD's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXD advanced for three days, in 270 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
RXD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Industry description
Advertisement